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Live attenuated vaccines remain the safest, most
cost-effective intervention against viral infections.
Because live vaccine strains are generated empiri-
cally and the basis for attenuation is usually ill de-
fined, many important viruses lack an efficient live
vaccine. Here, we present a general strategy for the
rational design of safe and effective live vaccines
that harnesses the microRNA-based gene-silencing
machinery to control viral replication. Using poliovi-
rus as a model, we demonstrate that insertion of
small miRNA homology sequences into a viral ge-
nome can restrict its tissue tropism, thereby prevent-
ing pathogenicity and yielding an attenuated viral
strain. Poliovirus strains engineered to become tar-
gets of neuronal-specific miRNAs lost their ability
to replicate in the central nervous system, leading to
significant attenuation of neurovirulence in infected
animals. Importantly, these viruses retained the
ability to replicate in nonneuronal tissues. As a
result, these engineered miRNA-regulated viruses
elicited strong protective immunity in mice without
producing disease.
INTRODUCTION
The use of vaccines to combat viral diseases is one of the great-
est public health successes of the last century. Annual mortality
rates in the United States attributed to RNA viruses, including
poliomyelitis, measles, mumps, and rubella, have been reduced
by more than 99.9% (CDC, 1999). A number of virus vaccine ap-
proaches have been developed, including live attenuated virus,
inactivated virus, production of viral proteins, and gene-delivery
vehicles expressing viral antigens (Graham and Crowe, 2007).
Live attenuated virus vaccines are the most effective method
of immunization because they activate all components of the
immune system, inducing both a balanced systemic and local
immune response and a broad humoral and cellular response
(Graham andCrowe, 2007; Zinkernagel, 2003). However, the po-Cell Hosttential risk of attenuated viruses reverting to the pathogenic phe-
notype is amajor concern, alongwith production and distribution
issues.
A major drawback in the development of live vaccines is the
lack of rational approaches to attenuate virus pathogenicity. Ide-
ally, a virus vaccine would replicate robustly in a limited number
of tissues, so as to elicit a complex and long-lasting immune re-
sponse, while at the same time not spreading to tissues where it
may cause disease. For instance, poliovirus replication in the gut
is not life threatening, while infection of the motor neurons in the
spinal cord and brainstem leads to poliomyelitis (Andino et al.,
1999;Wood andMacadam, 1997). The ability to rationally design
viral strains that are selectively disabled in their replication in
a given tissue could provide the basis for the development of
vaccines. Altering cell tropism of a virus by passaging it in cell
culture is the classic method for virus attenuation and vaccine
strain development. In this method, attenuation of the patho-
genic phenotype often results from the adaptation of the patho-
genic virus to the particular cell line(s), thereby reducing virus fit-
ness in specific organs and cell types within the vaccinee (Graff
et al., 1997). This approach permitted the development of a num-
ber of virus vaccines, but the empirical nature of such passaging
may alter the virus in unpredictable ways, and the number of new
virus vaccines developed over the years remains limited.
A new approach for limiting the pathogenic potential of polio-
virus by manipulating the error rate of the viral polymerase was
recently described (Arnold et al., 2005; Pfeiffer and Kirkegaard,
2005; Vignuzzi et al., 2006, 2008). By increasing polymerase
fidelity, the genetic diversity of the poliovirus population was
restricted, and virulencewas attenuated in an animalmodel of in-
fection (Pfeiffer and Kirkegaard, 2005; Vignuzzi et al., 2006). This
approach was subsequently used to engineer attenuated polio-
virus vaccines with improved stability (Vignuzzi et al., 2008).
However, the issue of limiting viral replication to specific tissues
remains a key aspect of developing attenuated virus vaccines. In
this report, we describe a rational strategy for controlling viral
replication by exploiting the regulatory capacity of the RNA inter-
ference (RNAi) gene-silencing machinery.
RNAi functions as an adaptive antiviral immune response in
plants and insects (Baulcombe, 2004; Sanchez-Vargas et al.,
2004; Voinnet, 2005), and the importance of RNAi during viral
infection in mammals is the focus of intense research. Evidence& Microbe 4, 239–248, September 11, 2008 ª2008 Elsevier Inc. 239
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chinery and mammalian viruses. Viruses employ strategies to
repress or usurp the RNAi machinery by encoding virus-derived
siRNAs, microRNAs (miRNA), and viral suppressors that target
components of the gene-silencing pathway (Cullen, 2006; van
Rij and Andino, 2006). miRNAs are a family of RNA species
that are structurally and functionally related to the short interfer-
ing RNAs (siRNA) that cause RNA silencing (Bartel, 2004). This
family of noncoding genes functions as posttranscriptional reg-
ulators of gene expression (He and Hannon, 2004). Mature
miRNAs are formed by two processing events. First, the nascent
miRNA transcripts are processed into pre-miRNA precursors
(70 nucleotides in length) in the nucleus by the RNase-III en-
zyme, Drosha. Next, the pre-miRNA is cleaved by a second
RNase-III enzyme, Dicer, in the cytoplasm to generate the 21–
25 nucleotide mature miRNAs (Bernstein et al., 2001; Denli
et al., 2004; Gregory et al., 2004; Grishok et al., 2001; Hutvagner
et al., 2001; Lee et al., 2002, 2003, 2004). Current data suggest
that miRNAs regulate gene expression through translational re-
pression or mRNA degradation (He and Hannon, 2004). miRNAs
can also act as siRNAs to guide cleavage of a perfect comple-
mentary sequence (Gitlin et al., 2005; Hutvagner et al., 2001).
ThismRNA-cleavage step of RNAi ismediated by the endonucle-
ase Argonaute2 (Ago2) within the context of the RNA-induced
silencing complex (RISC) (Meister et al., 2004; Rand et al., 2005).
miRNAs regulate numerous aspects of development and cel-
lular physiology. Accordingly, miRNA expression patterns are
tissue specific and developmentally timed such that each tissue
is defined by a characterized set of specific miRNAs (Bartel,
2004; Lagos-Quintana et al., 2002). For example, let-7a, identi-
fied in worms, encodes a temporally regulated miRNA that con-
trols the developmental transition from the L4 stage into the adult
(Abrahante et al., 2003; Lin et al., 2003; Reinhart et al., 2000). The
neuron-specific miRNA, miR-124, promotes mammalian neuro-
nal differentiation by a number of mechanisms (Cao et al., 2007;
Makeyev et al., 2007; Visvanathan et al., 2007). Interestingly, it
has been shown that expression of transgenes encoded by
gene therapy vectors can be regulated by endogenous miRNAs
(Brown et al., 2006, 2007). We hypothesized that the diverse
tissue-specific distribution of cellular miRNAs could also be
harnessed to regulate the tissue tropism of pathogenic human
viruses. Recently, interactions between endogenous miRNAs
and viruses have been reported, providing evidence that
miRNAs can effectively interact with viruses during their normal
life cycle (Cullen, 2006; Jopling et al., 2005; Lecellier et al., 2005).
To test our hypothesis, we exploited the regulatory capacity of
the miRNA machinery to control virus tropism and show that this
strategy reduces virus pathogenesis. We engineered poliovirus
carrying endogenous miRNA-complementary target sequences.
This virus is unable to replicate in cells expressing the corre-
sponding miRNA, thus producing an attenuated phenotype.
We further show that attenuation is due to the interaction
between the cellular miRNA and the viral target, inducing miRNA
repression. The restricted tissue tropism of these engineered
viruses results in an attenuated neurovirulent phenotype in a
mouse model of infection. Importantly, because the engineered
viruses can replicate in certain tissues, they elicit protective im-
munity against challenge with a pathogenic strain of poliovirus.
This approach provides a general mechanism for controlling viral240 Cell Host & Microbe 4, 239–248, September 11, 2008 ª2008 Elreplication in specific tissues to rationally design stable, attenu-
ated vaccines that can elicit long-lasting immunity.
RESULTS
A Rational Approach for Engineering
Stably Attenuated Viruses
To determine whether the miRNA gene-silencing machinery
could be used to rationally engineer viruses with tissue tropism
determined by the miRNA expression profiles, polioviruses
were constructed to contain two complementary miRNA target
sequence insertions. The two insertions were introduced into
the ‘‘variable’’ segment at the 30 end of the 50 untranslated region
(UTR) and between the structural and nonstructural genes within
the coding region (Figure 1A). These sites were previously shown
to tolerate large insertions without adverse effects to virus repli-
cation (Tang et al., 1997). The miRNA target sequences chosen
for this study are complementary to let-7a or miR-124a, and
the viruses carrying these insertions were designed as PV-L7
and PV-124, respectively (Figure 1B). We also constructed con-
trol viruses with modified miRNA target sequences to prevent
recognition and cleavage by these miRNAs, termed PV-L7M
and PV-124M viruses, respectively (Figure 1B).
To evaluate the ability of viruses containing these sequences
to replicate in tissue culture, one-step growth curves were per-
formed in HeLa cells that express let-7a but not miR-124a and
NTERA-2 cells that do not express either miRNA (Figure 1C,
lanes 1 and 2). In NTERA-2 cells, wild-type and engineered
viruses replicated with identical kinetics (Figure 2A), indicating
that the insertion of the miRNA target sequences did not impair
virus replication. In contrast, replication of PV-L7 virus was
severely compromised in HeLa cells, which express let-7a
(Figure 2A). Control PV-L7M virus carrying mutated let-7a target
sequences showed replication rates and final viral titers compa-
rable to those observed for wild-type virus (Figure 2A). PV-124
viral replication in HeLawas unaffected (data not shown), consis-
tent with the fact that the neuronal-specific miR-124a is not ex-
pressed in HeLa cells. To further characterize the replication of
PV-L7 in HeLa cells, RNA extracted from infected cells was an-
alyzed by semiquantitative RT-PCR (Figure 2B). The amount of
PCR product amplified from cells infected with wild-type and
PV-L7M was significantly higher at 6 hr compared to the starting
time of infection (0 hr, Figure 2B, lanes 4 and 7 and lanes 6 and 9).
This result indicates, as expected, that wild-type and PV-L7M vi-
rus RNA accumulates over the first 6 hr of infection. In contrast,
we observed a decrease in PV-L7 viral RNA over the same period
of time (Figure 2B, compare lanes 5 and 8). We conclude that, in
HeLa cells, the pairing of cellular let-7a and the target sequences
within PV-L7 leads to a decrease in viral RNA levels, thereby
attenuating PV-L7 viral replication.
The miRNA Machinery Mediates Attenuation
of Viral Replication
To directly examine the effect of miRNA let-7a in PV-L7 viral
growth, we measured viral replication in HeLa cells transfected
with miRNA inhibitors (anti-miRs). Anti-miRs are chemically
modified, single-stranded nucleic acids that are designed to
specifically bind and inhibit endogenous miRNA molecules.
PV-L7 replication was partially rescued by transfection withsevier Inc.
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inhibited in HeLa cells transfected with a control anti-miR (Fig-
ure 2C). The final virus titers (24 hr time point) for wild-type polio-
virus were 1003 greater than those levels observed for PV-L7 in
cells transfected with let-7a anti-miR. It is likely that residual cel-
lular let-7a, or newly processed mature miRNA, partially inhibit
viral replication in anti-miR-transfected HeLa cells. Similarly,
transfection efficiency is usually not perfect, so viral growth
remains inhibited in those untransfected cells. Nonetheless,
these data indicate that the inhibition of PV-L7 replication
depends on the availability of let-7a.
Figure 1. Engineering Viruses with Restricted Tissue Tropism
(A) Target sequences complementary to two distinct miRNAs (let-7a and
miR124a) were inserted into two locations within the poliovirus genome. The
50 site is located in the ‘‘variable’’ segment between the poliovirus internal
ribosome entry site (IRES) and the start codon. The 30 site is located between
the structural and nonstructural genes.
(B) Perfect sequence complementarity between the endogenous miRNA and
the target sequence inserted into the poliovirus genome is illustrated. Silence
mutations were engineered into the target sequences to create virus controls
that disrupt base pairing with the endogenous miRNA while conserving the
wild-type encoded amino acid sequence.
(C) Northern blot analysis of let-7a and miR-124a miRNA expression levels
observed in cell lines (HeLa and NTERA-2, lanes 1 and 2) and mouse tissues
(lanes 3–7).Cell Host &We next determined whether core components of the miRNA
machinery are required for PV-L7 replication control. To this end,
we transfected HeLa cells with siRNAs that specifically deplete
two core components of the miRNA machinery, Drosha and
Ago2 (human homolog, eIF2C2). Downregulation of both Drosha
and Ago2 resulted in a significant increase in PV-L7 replication in
HeLa cells (Figure 2D). Targeting Drosha and Ago2 increased
PV-L7 viral replication by 100- to 105-fold as compared to control
cells transfected with a siRNA targeting GAPDH (Figure 2D). To-
gether, these data establish that an interaction between the cel-
lular let-7a and the target sequences within the PV-L7 virus, by
triggering the ‘‘slicing’’ activity of Ago2 in RISC, account for the
potent inhibition of viral replication.
Controlling Viral Replication by Endogenous miRNAs
Strongly Attenuates Poliovirus Pathogenesis
The strong inhibition of PV-L7 replication by the miRNA machin-
ery in tissue culture cells prompted us to evaluate the effect of
miRNAs on poliovirus pathogenesis in an animal model of infec-
tion. First, we determined the 50% lethal dose (LD50) for wild-
type, PV-L7, PV-L7M, PV-124, and PV-124M viruses in trans-
genic mice expressing the human poliovirus receptor (cPVR,
Table 1). The LD50 of wild-type poliovirus is 2.2 3 10
6 infectious
particles (PFU). In comparison, the LD50 of PV-L7 and PV-124 vi-
ruses was greater than the highest dose administered, 1 3 108
PFU. Control viruses PV-L7M and PV-124M displayed LD50
values similar to wild-type, as expected. Intramuscular injection
of 108 PFUofwild-type virus into cPVRmice resulted in a rapid in-
vasionof thecentral nervoussystem, causingparalysis anddeath
within 6days (Figure 3A). A similar doseof 108PFUPV-L7andPV-
124 viruses resulted in no symptoms of paralysis or death among
20 injected mice (Figure 3A). In contrast, control PV-L7M and
PV-124M viruses carrying mutated miRNA target sites were fully
pathogenic (Figure 3A). Thus, insertion of miRNA target sites
strongly attenuates poliovirus in this murine model of infection.
In order to further characterize these viruses, similar experi-
mentswereperformed inPVR-transgenicmicedefective inab-In-
terferon (ab-IFN) signaling due to deletion of the ab-IFN receptor
(IFNARmice) (Ida-Hosonuma et al., 2005). Thesemice are signif-
icantly more susceptible to poliovirus infection, affording a larger
dynamic range for measuring viral pathogenicity and providing
a very sensitive host to investigate pathogenic properties of the
modified polioviruses PV-L7 and PV-124. Indeed, the LD50 value
of wild-type virus in this mouse background was 37 PFU, five or-
ders of magnitude lower than the LD50 observed in cPVR mice
(Table 1). Strikingly, PV-L7 viral pathogenesis was completely at-
tenuated in IFNARmice (Figure 3B), and themeasured LD50 value
for PV-L7 was greater than 108 PFU, the highest dose used. As
expected, the control PV-L7M virus displayed a wild-type patho-
genic phenotype with an LD50 value of 290 PFU (Figure 3B
and Table 1). PV-124 virus was also attenuated in IFNAR mice
(Table 1 and Figure 3C), albeit to a lesser degree than PV-L7.
These findings suggest that the ubiquitous expression of let-7a
is able to suppress viral replication more completely than
miR-124a, which is only expressed in the central nerve tissues.
miRNAs Control Poliovirus Tissue Tropism
We hypothesized that let-7a and miR-124a miRNAs would
control the replication of viruses encoding complementaryMicrobe 4, 239–248, September 11, 2008 ª2008 Elsevier Inc. 241
Cell Host & Microbe
Controlling Virus Tropism with Endogenous miRNAssequences selectively in tissues where these miRNAs are ex-
pressed. Furthermore, we expected that this tissue selectivity
would account for the observed differences in virulence of the
engineered viruses. To test these hypotheses, we examined viral
replication in various tissues obtained 6 days after infection of
mice inoculated intravenously with sublethal doses (0.1 LD50)
of wild-type or engineered viruses (Figure 4). Both control
viruses, PV-L7M and PV-124M, accumulated to wild-type levels
in the brain and spinal cord of the infected mice (Figures 4A and
4B). In contrast, PV-L7 and PV-124 virus failed to accumulate, or
only barely accumulated, in these tissues. We did not detect
PV-L7 in the brain or spinal cord of injected mice. Low levels
(102 PFU) of PV-124 could be isolated from brains of three of
the five infected mice measured, and one of these mice showed
a similarly low titer in the spinal cord 6 days after injection. How-
ever, these mice did not show any neuropathogenic side effects
associated with poliovirus infection. Notably, in the spleen, wild-
type levels of replication were observed for all viruses except
PV-L7, which was found at a lower level by one order of magni-
tude (Figure 4C).
Northern blot analysis revealed ubiquitous let-7a RNA accu-
mulation in all tissues examined, whereas miR-124 RNA was
found solely in the central nervous system (Figure 1C, lanes 3
to 7). These data correlate with the observations that PV-L7
Figure 2. Engineered PV-L7 Virus Exhibits Attenuated Replication Kinetics Due to Endogenous let-7a-Mediated Repression
(A) Replication kinetics of wild-type poliovirus (squares) and engineered viruses, PV-L7 (circles), and control PV-L7M (triangles) in the permissive (NTERA-2, white
symbols) and nonpermissive (HeLa, filled symbols) cell lines by virtue of endogenous let-7a expression. PV-L7 viral replication is attenuated in HeLa cells by six
orders of magnitude, whereas the PV-L7M control virus replicates with wild-type kinetics. Viral titer values represent the mean ± SD of three independent exper-
iments. Error bars, SD.
(B) RT-PCR analysis of total RNA extracted from HeLa cells infected with wild-type, PV-L7, or PV-L7M virus at time zero (lanes 4–6) and 6 hours postinfection
(lanes 7–9). We amplified by RT-PCR a 269 nt long fragment (amplicon), spanning the 50 target insertion site, from 200 ng total RNA. The molecular marker is
shown in lane 1. Lane 2 controls for the reverse transcription reaction, and lane 3 corresponds to RNA isolated from uninfected HeLa cells used as a template
for the RT-PCR reaction.
(C) Inhibition of endogenous let-7a using anti-mir technology rescues PV-L7 viral replication in the nonpermissive HeLa cells. HeLa cells were transfected with
small oligonucleotides corresponding to the let-7a complementary sequence (anti-mir let-7a, black symbols) or control nonspecific oligonucleotide (ctrl anti-mir,
white symbols). HeLa cells were then infected with wild-type poliovirus (squares) or engineered PV-L7 virus (circles). Viral titer values represent the mean ± SD of
three independent experiments. Error bars, SD.
(D) Knocking down core components of the RNAi machinery rescues PV-L7 replication. siRNAs targeting Ago2 (circles) and Drosha (triangles) partially rescues
replication of PV-L7 (white symbols) in the nonpermissive HeLa cells, while a siRNA targeting GAPDH has no effect (squares). Transfecting siRNAs has no effect
on wild-type poliovirus replication (WT, black symbols). Viral titer values represent the mean ± SD of three independent experiments. Error bars, SD.
242 Cell Host & Microbe 4, 239–248, September 11, 2008 ª2008 Elsevier Inc.
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all tissues, whereas PV-124 viral replication was permitted in
nonneuronal tissues. Thus, PV-124 replication in peripheral tis-
sues might allow the accumulation of mutations within the viral
target sequence to escape endogenous miR-124a RNA recogni-
tion in the central nervous system. In fact, sequence analysis of
PV-124 virus isolated from the spinal cord of the infected mouse
contained deletions of the miRNA targets at both loci (data not
shown). Of note, the live attenuated Sabin strains of poliovirus
currently used as a vaccine exhibit similar LD50 values in trans-
genic mice (Vignuzzi et al., 2008) as the engineered viruses char-
acterized in this study. We conclude that poliovirus recombi-
nants carrying miRNA target sites are highly attenuated in an
experimental model of infection.
miRNA-Restricted Polioviruses Are Promising Vaccine
Candidates
Next, we examined the immunogenic potential of PV-L7 and PV-
124 viruses in mice inoculated intraperitoneally with engineered
viruses. Neutralizing antibodies are considered a key correlate of
poliovirus vaccine efficacy. Sera collected from immunized mice
4 weeks after injection revealed that PV-124 virus induced high
levels of poliovirus-specific neutralizing antibodies (Figure 5A).
Mice immunizedwith UV-inactivated wild-type poliovirus elicited
a similar response to PV-L7-immunized mice, and titers for
mock-immunized mice (PBS) were below the detection level of
the assay. The neutralizing antibody response elicited by PV-
124 was 3-fold higher than in G64S-immunized mice (Figure 5A).
It was previously shown that the high-fidelity replication variant,
G64S, was a superior immunogen compared to the current
Sabin type 1 vaccine strain (Vignuzzi et al., 2008). These obser-
vations indicated that the immunogenic potential of PV-124 is
comparable or better than that of currently used vaccines, thus
strongly supporting further use of this technology for engineering
virus vaccines.
The high neutralizing antibody titers identified in the vacci-
nated animals suggested that the immunizedmicewould be pro-
tected from a lethal challenge of wild-type pathogenic virus. To
examine this possibility, 4 weeks after intraperitoneal immuniza-
tions, 20 mice from each set were challenged with a lethal
amount (10 LD50) of wild-type poliovirus via an intramuscular in-
jection. Of the 20mice immunized with the engineered poliovirus
PV-124, 18 were completely protected against a lethal challenge
of wild-type poliovirus (Figure 5B). In comparison, 50% of the
animals immunized with PV-L7 were protected. Mice receiving
Table 1. Engineered PV-L7 and PV-124 Viruses Are Less Virulent
Than Wild Type Poliovirus
LD50(PFU)
PVR+ mice INFR/, PVR+
Wild-type 2.2 3 106 37
PV-L7 >1 3 109 2.0 3 108
PV-L7M 6.4 3 106 290
PV-124 >1 3 109 1.3 3 104
PV-124M 1.5 3 107 1400
LD50 values were calculated for each virus in both cPVR and IFNAR mice
using the Reed and Muench method.Cell HostUV-inactivated wild-type poliovirus vaccinations were only par-
tially protected compared to PBS-treated control mice. These
results indicated that PV-124 and PV-L7 induced neutralizing an-
tibody responses that conferred protective immunity to a very
stringent test of viral infection. The production of neutralizing an-
tibodies in immunized mice correlated well with the percentage
of mice surviving a lethal dose of pathogenic virus.
To further examine the protection afforded by PV-L7 immuni-
zations, we conducted similar experiments in IFNAR mice. At 1
month after intraperitoneal injections, mice immunized with 107
PFU PV-L7 were challenged with either 10 LD50 or 10
4 LD50 via
intramuscular injection. Seventy percent of mice survived the se-
verely lethal 104 LD50 dose, and all of the immunized mice were
protected against 10 LD50 injection of wild-type poliovirus
(Figure 5B). In comparison, mice treated with UV-inactivated
virus and PBS were not protected at all (Figure 5B). These data
demonstrate the efficacy of these viruses as vaccine candidates
and validate this approach as an effective strategy for rationally
engineering live attenuated virus vaccines.
DISCUSSION
Here, we describe a strategy for rationally engineering live atten-
uated virus vaccines. Our approach takes advantage of the tis-
sue-specific expression patterns of miRNAs and employs the
nucleic acid-based RNAi response to substantially control virus
replication in tissues where the virus causes disease. ThemiRNA
complementary sequences engineered into the virus genome
are targeted by the miRNA/RNAi machinery, thus inhibiting
virus replication in a tissue-specific fashion. Importantly, these
engineered viruses retained their replicative capacity while
exhibiting attenuated neurovirulence, thus permitting the devel-
opment of an effective immune response. Production of high
levels of neutralizing antibodies established the immunogenicity
of these test strains. Mice vaccinated with these vaccine candi-
dates induced comparable neutralizing antibody titers to those
observed for the Sabin type 1 poliovirus vaccine strain (Vignuzzi
et al., 2008). Importantly, immunized mice were protected
against lethal challenges of pathogenic wild-type virus. We con-
clude that this strategy can be used to specifically reduce viral
pathogenicity and create viable vaccine candidates.
A unique and exciting advantage of our new approach to ratio-
nally engineer live vaccines is its versatility, which may be appli-
cable to a wide variety of viruses. Cellular miRNAs have been im-
plicated in fundamental biological processes, and each cell type
displays a particular miRNA repertoire (Bartel, 2004). These cel-
lular miRNAs could be used to effectively control viral replication
of a wide variety of viruses with different pathogenic profiles in a
tissue-specific manner. For example, miRNA expression profiles
have been effectively exploited to regulate transgene expression
from lentiviral vectors according to tissue, lineage, and differen-
tiation state (Brown et al., 2007). Another advantage of this
approach for vaccine production is that viral replication remains
robust in tissues without the targeting miRNA, thus allowing
activation of multiple components of the immune system to elicit
a more complete and long-lasting protective immunity. Impor-
tantly, this technology may also be applicable to DNA viruses
and negative-strand RNA viruses (Edge et al., 2008). We feel
that this strategy may pave the way for the development of& Microbe 4, 239–248, September 11, 2008 ª2008 Elsevier Inc. 243
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Neuropathogenicity in Transgenic Mice
Percentage of (A) cPVR mice and (B and C) IFNAR mice surviving intra-
muscular injections of different doses (108–103 PFU); n = 20 mice per
group.
(A) cPVR mice infected with 108 PFU PV-L7 (filled squares) and PV-124 (filled
squares) viruses are unaffected, whereas mice infected with control viruses,
PV-L7M (filled triangles) and PV-124M (filled circles), and wild-type (white
squares) poliovirus do not survive past day 6.244 Cell Host & Microbe 4, 239–248, September 11, 2008 ª2008 Elsafe and efficacious vaccines to target a wide range of emerging
and established viral diseases that have been refractory to vac-
cine development.
Our strategy to engineer polioviruses that are responsive to
miRNA regulation was successful at precluding viral replication
in cells expressing the target miRNA. PV-L7 replication was at-
tenuated in HeLa cells, and that attenuation correlated with a de-
crease in viral RNA levels 6 hr after infection. However, knock-
down of Ago2 rescued viral replication in tissue culture
(Figure 2D), implicating the catalytic ‘‘slicer’’ component of the
RNAi machinery as a key factor of the virus control mechanism.
Previous data in our lab demonstrated that let-7a could act as
a siRNA to direct the cleavage of a perfect complementary viral
target RNA (Gitlin et al., 2002, 2005) and only Ago2 can catalyze
cleavage of complementary target RNAs (Forstemann et al.,
2007; Meister et al., 2004). Based on these data, we propose
that Ago2 can use endogenousmiRNAs to catalyze the cleavage
of viral RNA containing perfect complementary target sites
to control virus replication in specific tissues and attenuate
virulence.
One concern with attenuated vaccines is reversion to a virulent
phenotype. Viral escape from RNAi suppression has been de-
scribed (Boden et al., 2003; Das et al., 2004; Gitlin et al., 2002,
2005; Lecellier et al., 2005; Wilson and Richardson, 2005). In
these reports, single mismatches within the targeted region or
entire deletions generated RNAi escape mutants. To prevent
viral escape, multiple miRNA complementary target sequences
were introduced within the viral genome. Indeed, we did not ob-
serve let-7a RNA escape mutants in experiments investigating
PV-L7 viral replication. On the other hand, virus isolated from
the spinal cord of mice infected with PV-124 virus did contain
partial deletions of both miR-124a target sequences. However,
even though thesemutations disrupt the cellular miRNA/viral tar-
get hybrid, disease symptoms were not observed in these mice.
It is possible that the remaining partial complementarity to miR-
124a resulted in a repression of PV-124 translation. Mice vacci-
nated with PV-124 show a higher neutralizing antibody response
and complete protection from lethal challenge as compared to
PV-L7 immunized animals. However, the increased efficacy ob-
served for PV-124 correlates with a decrease in safety. Clearly,
these results demonstrate that, although PV-L7 is safer than
the PV-124 vaccine strain, the latter is as efficacious as the
currently used sabin vaccine.
Viruses could also be engineeredwith a combination ofmiRNA
target sequences to increase cell selectivity, eliminate the poten-
tial for cytopathic side effects, and limit escape from replication-
silencing activity. To further prevent potential problems associ-
ated with viral escape, a rational combinatorial approach could
be utilized, incorporating polymerase fidelity into viruses carrying
multiple miRNA target sequences. Thus, our approach may be
complementary to a recently described method for vaccine
design that exploits the observation that increasing replication
(B) IFNARmice infected with 107 PFU of PV-L7 (filled squares) virus all survive,
whereas most mice infected with 103 PFU wild-type poliovirus (white squares)
and the PV-L7M control virus (filled circles) were paralyzed by day 11.
(C) PV-124 virus is attenuated in IFNAR mice, albeit less dramatically than
PV-L7 infected IFNAR mice. The white and black squares indicate wild-type
and PV-124, respectively.sevier Inc.
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A set of five cPVRmice was infected intravenously with each engineered virus.
Virus isolated from the brain (A), spinal cord (B), and spleen (C) was analyzed
by a standard plaque assay 6 days postinfection. Viral titers (PFU/ml), normal-
ized by tissue mass, observed in the three tissues are plotted for five mice
infected with each virus. Black squares designate wild-type; white squares,Cell Host &fidelity attenuates pathogenicity (Vignuzzi et al., 2008). Together,
these strategies could effectively increase genetic stability with-
out compromising replication robustness and bestow additional
safeguards upon these virus vaccines to improve current
vaccines. However, obtaining high-fidelity variants may not be
straightforward for all viruses. Therefore, our new miRNA-based
approach provides a more flexible, general alternative for
rationally designing attenuated live vaccines, which may allow
the rapid production of vaccines in case of an emerging viral
threat.
While our work has focused on miRNA-mediated attenuation
of live vaccines, this technology is likely to be applicable to other
viral-based therapeutics. For example, the insertion of a broadly
expressed target sequence, such as let-7a, into a pathogenic
virus may provide an additional safeguard against accidental in-
fection when large amounts of virus are produced for inactivated
vaccines. Similarly, incorporating miRNA target sequences into
gene therapy viral vectors or oncolytic viruses may improve their
safety and minimize off-target effects. Therefore, further devel-
opment of this technology may have broad implication for the
fine-tuning of cancer, gene, and vaccine therapies.
EXPERIMENTAL PROCEDURES
Molecular Biology and Viruses
Plasmid prib(+)XpAlong (Herold and Andino, 2001), wild-type poliovirus type 1
Mahoney cDNA, was engineered to contain unique restriction sites in the
50-UTR (BssHII and SacI) and 2A site (EcoRI and XhoI) to facilitate cloning
the miRNA target sequences into the plasmid. Complementary oligos (Elim
Biopharmaceuticals, Hayward, CA) were annealed in 40 mM Tris (pH 7.5),
20 mM MgCl2, and 50 mM NaCl for 2 min at 90C and allowed to slowly
cool to room temperature. To construct the viruses, we inserted EcoRI and
XhoI restriction site-flanked fragments into the cDNA of the poliovirus genome
at the 2A position. Positive clones were subsequently used to insert a second
BssHII and SacI restriction site-flanked fragment into the cDNA in the 50-UTR.
The DNA sequences for the PV-L7 oligos at the 2A and 50-UTR sites are 50-A
ATTCAACTATACAACCTACTACCTCAGTCGAC-30 and 50-TCGAGTCGACTG
AGGTAGTAGGTTGTATAGTTG-30, 50-CGCGCGGCCGAACTATACAACCTAC
TACCTCAGAGCT-30 and 50-CTGAGGTAGTAGGTTGTATAGTTCGGCCG-30,
respectively. The DNA sequences for the PV-L7M oligos at the 2A and
50-UTRsitesare50-AATTCAATTACACGACTTATTATTTGAGTCGAC-30 and50-T
CGAGTCGACTCAAATAATAAGTCGTGTAATTG-30, 50-CGCGCGGCCGAATT
ACACGACTTATTATTTGAGAGCT-30 and 50-CTCAAATAATAAGTCGTGTAAT
TCGGCCG-30, respectively. The DNA sequences for the PV-124 oligos at the
2A and 50-UTR sites are 50-AATTCGTCGACAGTGGCATTCACCGCGT
GCCTTAAC-30 and 50-TCGAGTTAAGGCACGCGGTGAATGCCACTGTCGAC
G-30, 50-CGCGCCGGCCGAGTGGCATTCACCGCGTGCCTTAAGAGCT-30 and
50-CTTAAGGCACGCGGTGAATGCCACTCGGCCGG-30, respectively. The DNA
sequences for the PV-124M oligos at the 2A and 50-UTR sites are 50-A
ATTCGTCGACTGTAGCGTTAACTGCATGGCGCAGC-30 and 50-TCGAGCTG
CGCCATGCAGTTAACGCTACAGTCGACG-30, 50-CGCGCCGGCCGTGTAGC
GTTAACTGCATGGCGCAGGAGCT-30 and 50-CCTGCGCCATGCAGTTAAC
GCTACACGGCCGG-30, respectively. The DNA sequences for the control vi-
ruses (PV-L7M and PV-124M) were generated by altering the codon sequence
PV-L7; black circles, PV-L7M; white circles, PV-124; and black triangles,
PV-124M. In the brain and spinal cord, PV-L7- and PV-124-infected mice ex-
hibit viral titers that are four to six orders of magnitude lower than viral titers
observed in mice infected with wild-type poliovirus and the control viruses,
PV-L7M and PV-124M. PV-L7 viral replication is measurable in the spleen
but is still an order of magnitude lower than viral titers observed in mice
infected with the other viruses. In the spleen, wild-type levels are observed
for PV-124 virus.Microbe 4, 239–248, September 11, 2008 ª2008 Elsevier Inc. 245
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amino acid. We produced virus stocks by electroporation of 20 mg in vitro tran-
scribed RNA, generated from the engineered plasmids above, into 800 ml
NTERA-2 cells (ATCCHTB-106, 53 106 cells/ml) in a 4mmcuvettewith the fol-
lowing pulse: 300 V, 24 U, and 500 mF. The progeny were passaged twice at
a highmultiplicity of infection (MOI=10) at 37C inNTERA-2 cells, and this latter
passage viruswas used for the described experiments. RT-PCRof viral RNA as
previously described (Vignuzzi et al., 2006) was performed to confirm that the
insertion sequences were unaltered in the viral stocks.
Figure 5. Infection with PV-L7 or PV-124 Virus Induces High Levels
of Neutralizing Antibody and Confers Immunity against a Lethal
Challenge with Wild-Type Poliovirus
(A) Neutralizing antibody titers (reciprocal of the serum dilution able to neutral-
ize 100 TCID50 of wild-type poliovirus) were determined for serum collected
from immunizedmice. Data for individualmice (black squares specify UV-inac-
tivated wild-type virus; white squares, PV-L7; black circles, PV-124; white cir-
cles, G64S; and black triangles, PBS) and the group average (bar) are shown.
Titers for PBS-immunized mice were below the detection level of the assay,
indicated by the dashed line.
(B) cPVR and IFNAR mice were immunized with either phosphate buffer saline
(PBS) or 13 107 PFU (0.1 LD50) of wild-type irradiated virus, PV-L7 virus, or PV-
124 virus. At 4 weeks after immunization, serumwas collected. Micewere sub-
sequently challenged with either 10 LD50 or 10
4 LD50 of wild-type poliovirus via
intramuscular injection. The numbers of mice surviving are indicated. PV-124-
immunized cPVR mice are protected against a lethal challenge of wild-type
poliovirus, whereas cPVR mice immunized with PV-L7 and UV-inactivated
wild-type virus are much less protected. PV-L7-immunized IFNAR mice were
protected against a lethal challenge with 10 LD50 of wild-type poliovirus, and
70%of the immunized IFNARmice even survived a challenge dose of 104 LD50.246 Cell Host & Microbe 4, 239–248, September 11, 2008 ª2008 ElsNorthern Blot Analysis
Total RNA from cells (HeLa and NTERA-2) and tissues (brain, spleen, kidney,
muscle, and spinal cord) from 8-week-old cPVR mice was isolated using
TRIzol reagent (Invitrogen, Carlsbad, CA) according to themanufacturer’s sug-
gested protocol. Electrophoresis of 20 mg total RNA was resolved in 12%
acrylamide-urea denaturing gels at 400 V for 1 hr, followed by 500 V until the
bromophenol blue dye reached the bottom of the gel. RNA was subsequently
transferred onto Hybond N+ membranes (Amersham) for 2 hr at 225 mA using
a Semi-Dry Transfer Cell (Bio-Rad). Themembraneswere crosslinked at 1,2003
100 mJ and dried overnight. DNA oligos (ELIM Biopharmaceuticals) comple-
mentary to let-7a (AACTATACAACCTACTACCTCA), miR-124a (TGGCATTC
ACCGCGTGCCTTAA), and U6 (TGGAACGCTTCACGATTTTG) were end-
labeled with g-32P by T4 kinase (NEB), and G-25 spin columns (Amersham)
were used to remove unincorporated nucleotides. The probes were hybridized
tomembranes inULTRAhyb-oligobuffer (Ambion) overnight at 37C.Themem-
branes were washed twice with 23 SSC/0.1%SDS at 37C for 30min. Images
were obtained using a Typhoon Variable Mode Imager (GE Healthcare).
One-Step Growth Curve Studies
These assays characterizing virus growth in tissue culture have been previ-
ously described (Vignuzzi et al., 2006). The data presented here represents
three independent experiments for each virus at each time point (error bars
are included). Cell lines used in these studies include HeLa S3 (ATCC CCL-
2.2) grown in suspension at 37C in SMEM (Lonza) media supplemented
with 10% fetal bovine serum (Sigma) and NTERA-2 (ATCC HTB-106) grown
adherently at 37C in DMEM/High glucose media supplemented with 10%
fetal bovine serum (Sigma). Standard plaque assays to measure PV-L7 viral
replication were performed on NTERA-2 monolayers, and all other viruses
were titered on HeLa cells. Slight modifications were made to the protocol
when studying viral growth in cells that were transfected with Ambion (Foster
City, CA) anti-miR miRNA inhibitors or Dharmacon (Lafayette, CO) siRNAs. In
both cases, 2.5 3 105 cells were seeded in wells of a 12-well plate and trans-
fectedwith 30 pmol anti-miR inhibitor specific for let-7a, 30 pmol anti-miR con-
trol inhibitor, or 20 pmol Dharmacon siRNA according to the Lipofectamine
2000 (Invitrogen, Carlsbad, CA) manufacturer’s suggested protocol for siRNA
transfections. Themedia was changed after 12 hr and viral infections were car-
ried out 24 hr later. The siRNA sense and antisense sequences used to target
the human Ago2 homolog eIF2C2 are GGAAAAUGAUGCUGAAUAUUU and
AUAUUCAGCAUCAUUUUCCUU, respectively. The siRNA sense and anti-
sense sequences used to target the dsRNA-specific RNase-III-type endonu-
clease Drosha are GAGUAGGCUUCGUGACUUAUU and UAAGUCACGA
AGCCUACUCUU, respectively. A GAPDH siRNA from Dharmacon was used
as a control in these experiments. The oligonucleotides were converted to
the 20-hydroxyl, annealed, and desalted prior to receiving the duplex siRNAs.
RT-PCR of Viral RNA from Infected Cells
The experiments described here are slightly modified from previously pub-
lished data (Vignuzzi et al., 2006). Each well of a 6-well plate was seeded
with 1 3 106 HeLa cells and infected the following day with wild-type, PV-L7,
or PV-L7M virus at a multiplicity of infection of 10 (MOI = 10). The infections
were performed similar to the one-step growth curves described above with
a slight modification. Virus absorption was carried out at 4C to allow receptor
binding while preventing cellular internalization. The cells were washed twice
with cold PBS, and warm DMEM/High glucose media supplemented with
10% fetal bovine serum (Sigma) was subsequently added. TRIzol (Invitrogen,
Ca) extraction of total RNA from the adherent cells was carried out according
to the manufacturer’s suggested protocol at various times following infection.
A Thermoscript RT-PCR kit (Invitrogen, Ca) was used to amplify a 269 nt frag-
ment, spanning the 50 target insertion site, from 200 ng total RNA. The forward
and reverse primer sequences for the PCR reaction are GGCTGCTTATGGTG
ACAATCACAG and GTGGTGTAATTAATGGTAGAACCACC, respectively. The
PCR reaction was cycled 25 times, and the fragments were resolved on a 2%
agarose gel.
Infection of Susceptible Mice
The University of California, San Francisco Institutional Animal Care and Use
Committee (IACUC) approved the protocols for the mouse studies described
here. In these experiments, we used 6- to 8-week-old cPVR and IFNARevier Inc.
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Controlling Virus Tropism with Endogenous miRNAstransgenic mice expressing the poliovirus receptor. The following inoculations
were performedwhile themice were under anesthesia: intramuscular (23 50 ml,
one in each quadriceps), intraperitoneal (250 ml), and intravenous (100 ml, tail
vein). Mice were monitored daily for the onset of paralysis and euthanized
when total paralysis was imminent. In order to determine the LD50 values ac-
cording to the Reed and Muench method, 20 mice were infected intramuscu-
larly with serial dilutions of virus. To analyze viral tissue tropism, we harvested
whole organs from five mice in each group that had been infected intrave-
nously and homogenized the organs in 2 ml PBS with a T1 Basic S1 disperser
from Ika Works, Inc. (Wilmington, NC). The tissue homogenates were clarified
and titered on HeLa cells by standard plaque assay. Neutralization assays
were performed with sera collected from five mice (from a group of 20 cPVR
mice) 1 month after receiving intraperitoneal immunizations with PBS, 107
PFU UV-inactivated wild-type, PV-L7, or PV-124 virus. 100 3 the 50% tissue
culture infectious dose (TCID50) of wild-type poliovirus was treated for 2 hr
with serial dilutions of sera (performed in octuplicate). The serial dilution was
determined that completely neutralized 100TCID50 by incubating samples on
1 3 104 HeLa cells (DMEM, 2% final FBS concentration) in 96-well plates for
1 week. Using the Reed andMuenchmethod, the neutralizing antibody dilution
was determined. The reciprocal of this dilution is the neutralizing antibody titer
that is represented in the graph. Following sera collection, the groups of
20 mice (or group of 10 IFNAR mice) were challenged intramuscularly with
10 LD50 (and 10
4 LD50 in immunized IFNAR mice) wild-type poliovirus and
subsequently monitored for paralysis.
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